vendredi 30 novembre 2018

Onco Actu du 30 novembre 2018


1. Biologie

Inconspicuous protein key to deadly blood cancer [Cold Spring Harbor Lab]

1.4 Biologie - Technos

NIH director says there’s work to do on regulating genome editing globally [STAT]

Opinion: Don’t Ban the Use of CRISPR in Embryos [The Scientist]

3.1.1 Prévention - Tabac - e-cigs

FDA warns e-cigarette liquid maker against products resembling food for kids [Reuters]

4.12 Biopsies liquides

Liquid Biopsy Is Effective at Guiding Treatment of Lung Cancer, Study Finds [Memorial Sloan kettering Cancer Center]

4.9 Dép., diag. & prono. - Sein

New Analysis of NSABP Randomized B-20 Study Confirms Patients with Oncotype DX Breast Recurrence Score® Results Greater Than 25 Have Life-saving Benefit from Chemotherapy, Reinforcing the Conclusions of the Landmark TAILORx Study [Genomic Health]

5.1 Traitements - Pré-clinique

Measuring cancer cell “fitness” reveals drug susceptibility [MIT News]

5.10 Traitements - Essais

ASCO and Friends of Cancer Research Applaud NCI’s Expansion of Clinical Trial Eligibility Criteria [ASCO]

5.12 Immunothérapies

An interview with Nobel Prize-winning cancer immunologist Jim Allison [BiopharmaDive]

The number of I/O cancer drugs in the clinic continues to swell at an explosive pace — offering new hope, fresh concerns [EndPoints]

5.12.1 Immunothérapies - partenariats

Cancer Research UK, the Francis Crick Institute and Bristol-Myers Squibb join forces to map out lung cancer immunology [Cancer Research UK]

5.12.8 Immunothérapies - Economie

Merck pushes small batch of price hikes, including top-selling Keytruda and Gardasil [FiercePharma]

Merck increased list prices on Keytruda, Gardasil in November [BiopharmaDive]

Immunotherapy drug made available for some NHS patients with advanced skin cancer after surgery [cancer Research UK]

5.3 Traitements - FDA, EMA, NICE...

FDA to follow EMA with move from London to Amsterdam [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA,...)

FDA Approves New Targeted Drug for Leukemia Tested at University of Pennsylvania [Penn Medicine]

Astellas’ Xospata wins FDA nod in AML, with Daiichi competition looming [FiercePharma]

5.4 Traitements - Economie

Targeted cancer drug made available for some NHS liver cancer patients [Cancer Research UK]

Life extending treatment for patients with advanced liver cancer recommended by NICE [NICE]

5.6 ESMO

ESMO Immuno-Oncology Congress: Where the Community of Stakeholders Meets [ESMO]

5.7.1 SABCS-communiqués

Lilly to Present Clinical Data for Verzenio® (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS [Lilly]

5.8.2 ASH - Pharma

nanoString Technologies Highlights Advances in Precision Oncology at the 60th Annual Meeting of the American Society of Hematology [nanoString]

Bristol-Myers Squibb to Highlight New Data from Broad Oncology Portfolio at the 60th American Society of Hematology Annual Meeting [BMS]

6.1 Observation

U.S. life expectancy declines again in sobering ‘wake-up call’ [STAT]

6.10 Politiques

Beware the rise of the radical right [Nature]

6.7.3 DMP

Cultural shift needed to keep trust in use of patient data [Queen Mary University of London]

6.9 Controverses

Under protest, OSU cancer researcher dogged by misconduct allegations stepping down as department chair [Retraction Watch]